Postoperative complications after splenectomy for hematologic malignancies

Annals of Surgery

Volumn 223, Issue 3, 1996, Pages 290-296

  Horowitz, Joel ^a   Smith, Judy L ^a   Weber, Thomas K ^a   Rodriguez Bigas, Miguel A ^a   Petrelli, Nicholas J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; HAIRY CELL LEUKEMIA; HUMAN; HYPERSPLENISM; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POSTOPERATIVE COMPLICATION; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLENECTOMY; SPLENOMEGALY;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; INCIDENCE; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SPLENECTOMY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0029871184     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199603000-00010     Document Type: Article

References (32)

1. Kinsella TJ, Glatstein E. Staging Laparotomy and splenectomy for Hodgkin's disease: current status. Cancer Invest 1983; 1(1):87-91.
2. Ketley NJ, Mills MJ, Traub NE, Brown AA. Haematological splenectomy: changing indications and complications. Clin Lab Haemat 1992; 179-188.
3. Carbonne PP, Kaplan HS, Mussloff K, et al. Report of Committee on Hodgkin's disease staging classification. Cancer Res 1971; 31:1860-1861.
4. Adler S, Stutzman L, Sokal JE, Mittelman A. Splenectomy for hematologic depression in lymphocytic lymphoma and leukemia. Cancer 1975; 33:521-528.
5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Statis Assoc 1956; 153:457-486.
6. Malmaeus J, Akre T, Adami HO, Hagberg H. Early postoperative course following elective splenectomy in haematological diseases: a high complication rate in patients with myeloproliferative disorders. Br J Surg 1986; 73:720-723.
7. Musser G, Lasar G, Hocking W, Busettil RW. Splenectomy for hematologic disease. Ann Surg 1984; 200:40-45.
8. Ellison EG, Fabri PJ. Complications of splenectomy: etiology, prevention and management. Surg Clin North Am 1983; 63:1313-1330.
9. Dawson AA, Jones PI, King DJ. Splenectomy in the management of haematological disease. Br J Surg 1987; 74:353-357.
10. Johansson T, Bostrom H, Sjodahl R, Ihse I. Splenectomy for haematological diseases. Acta Chir Scand 1990; 156:83-86.
11. Wilhelm MC, Jones RE, McGehee R, et al. Splenectomy in hematologic disorder: the ever-changing indications. Ann Surg 1988; 207:581-589.
12. Hays DM, Ternberg JL, Chen TT, et al. Complications related to 234 staging laparotomies performed in the intergroup Hodgkin's disease in childhood study. Surgery 1984; 90:471-478.
13. Laws HL, Burlingame MW, Carpenter JT, et al. Splenectomy for hematologic disease. Surg Gynecol Obstet 1979; 149:509-512.
14. Sandusky WR, Leavell BS, Benjamin BJ. Splenectomy: indications and results in hematologic disorders. Ann Surg 1964; 159:695-709.
15. Mitchell A, Morris PJ. Splenectomy for malignant lymphomas. World J Surg 1985; 9:444-448.
16. Damestek HL, Ellis LD. Hematologic indications for splenectomy. Surg Clin North Am 1975; 55:253-275.
17. Rosner F, Zarrabi MH. Late infections following splenectomy in Hodgkin's disease. Cancer Invest 1983; 1:57-65.
18. Schreiber DP, Jacobs C, Rosenberg SA, et al. The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and Non-Hodgkin's lymphomas. Rad Oncol Biol Physics 1985; 11:31-36.
19. Marble KR, Deckers PJ, Kern KA. Changing role of splenectomy for hematologic disease. J Surg Onc 1993; 52:169-71.
20. Swerdlow AJ, Douglas AJ, Vaughan-Hudson G, et al. Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy. Br J Cancer 1993; 68:1005-1111.
21. Tura S, Fiacchini M, Zinzani PL, et al. Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J Clin Oncol 1993; 11:925-930.
22. Mellemkjoer L, Olson JH, Linet MS, et al. Cancer risk after splenectomy. Cancer 1995; 75:577-583.
23. Dietrich PY, Henry-Amar M, Cossel JM, et al. Secondary primary cancers in patients continuously disease-free from Hodgkin's disease: a prospective role for the spleen? Blood 1994; 84:1209-1215.
24. Salvagno L, Simorato L, Soraru M, et al. Secondary leukemia following treatment for Hodgkin's disease. Tumori 1993; 79:103-107.
25. Saven A, Piro LD. Treatment of hairy cell leukemia. Blood 1992; 79:1111-1120.
26. Spiers AS, Moore D, Leth PA, et al. Remissions in hairy cell leukemia with Pentostatin (2-deoxycoformycin). N Engl J Med 1987; 316:825-830.
27. Piro CD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxy-adenosine. N Engl J Med 1990; 322:1117-1121.
28. Nies BA, Creger WP. Tolerance of chemotherapy following splenectomy for leukopenia or thrombocytopenia in patients with malignant lymphomas. Cancer 1967; 29:558-562.
29. Gill PG, Souter RG, Morris PJ. Splenectomy for hypersplenism in malignant lymphomas. Br J Surg 1981; 68:29-33.
30. Baccarani M. Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia: the Italian Cooperative Study Group on chronic Myeloid Leukemia. Cancer 1984; 54: 333-338.
31. 1-positive chronic granulocyte leukemia, including an analysis of prognostic features: Medical Research Council Working Party for Therapeutic Trials in Leukemia. Br J Haematology 1983; 54:415-430.
32. Baughan ASJ, Worsley AM, McCarthy DM, et al. Haematological reconsitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocyte leukemia: the influence of previous splenectomy. Br J Haematology 1984; 56:445-454.